The American Hospital Association is once again raising concerns about how a major drugmaker handles the government’s 340B ...
Data sovereignty key navigating 340B's future helps healthcare leaders build integrated data systems for compliance and financial resilience in 2026.
HHS may reconsider blocked 340B rebate pilot after courts halt the program, signaling potential changes for drug discount policies in 2024.
A federal judge granted a temporary restraining order to block a pilot program aimed at keeping better tabs on the ...
The 340B Program has continued to undergo significant upheaval in 2024 that has the potential to bring about impactful changes to how the 340B Program operates moving forward. These developments have ...
Health Affairs' Rob Lott interviews Sayeh Nikpay of the University of Minnesota about her recent paper exploring how The Medicaid Drug Rebate Program and the 340B Program interact in ways that can ...
The American Hospital Association (AHA) expresses serious concerns with the recent announcement by Eli Lilly and Company (Lilly) to require 340B covered entities to submit claims data for all ...
The 340B Drug Pricing Program (340B Program) is no stranger to controversy. We have previously covered the ongoing contract pharmacy legal battles and the new alternative dispute resolution process.
Senator calls on Congress to increase oversight of the 340B Drug Pricing Program by requiring participating providers to complete annual reports on program savings and revenues. If your health system ...
The 340B Drug Pricing Program was created to help a targeted group of safety net providers care for low-income and uninsured patients. First enacted as part of the Veterans Healthcare Act of 1992, ...
What does it mean to be a patient? For some, it means access to the best doctors and hospitals. For others, it means a courageous battle against a chronic, and perhaps incurable disease. And for many, ...
Continued support of 340B is vital for diverse communities and small business owners in the state.